Pharmacyclics Stock Hits New 52-Week High (PCYC)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

NEW YORK ( TheStreet) -- Pharmacyclics Incorporated (Nasdaq: PCYC) hit a new 52-week high Wednesday as it is currently trading at $60.76, above its previous 52-week high of $60.05 with 165,851 shares traded as of 10 a.m. ET. Average volume has been 1.3 million shares over the past 30 days.

Pharmacyclics has a market cap of $3.89 billion and is part of the health care sector and drugs industry. Shares are up 282% year to date as of the close of trading on Tuesday.

Pharmacyclics, Inc. operates as a clinical-stage biopharmaceutical company focusing on discovering, developing, and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. The company has a P/E ratio of 262.5, below the average drugs industry P/E ratio of 281.9 and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Pharmacyclics as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, premium valuation and weak operating cash flow. You can view the full Pharmacyclics Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.
null

If you liked this article you might like

Johnson & Johnson Looks for New Deal That's Just Right

The Nominees for Best Biopharma CEO of 2015 Are...

Jim Cramer's 'Mad Money' Recap: Here's How Oil, the Fed and China Pushed Markets Up

AXON, REGN, BURL, FIVE: Jim Cramer's Views

The 10 Biggest U.S. M&A Deals in 2015